

Commitment to Communication

From your Provider Relations team.



2 Executive Park Drive • Bedford, NH 03110

Maternal & Infant FDA Approved Solutions for RSV

January 29, 2024

When it comes to RSV, you call the shots. As a trusted partner in the healthcare decisions of those you care for, we are committed to providing you timely information that helps promote shared decision making so your patients can make informed decisions on how to best protect their infant against respiratory syncytial virus (RSV). Your patients trust you more than any other source when it comes to vaccines. And your recommendation is the most effective way to ensure they get the ones they need.

RSV is the leading cause of childhood respiratory illness in the United States, resulting in thousands of hospitalizations and hundreds of deaths per year. The Food and Drug Administration (FDA) has approved, and The Centers for Disease Control and Prevention's (CDC) recommends maternal RSV vaccine and an infant RSV monoclonal antibody providing two opportunities to protect against the negative side-effects of RSV.

For the 2023-2024 RSV season, there are known supply shortages of the infant RSV Monoclonal Antibody Nirsevimab. In areas with shortages, guidance is to encourage maternal RSV vaccination as an alternative.

Infant RSV Monoclonal Antibody (Nirsevimab)

- A single intramuscular injection for infants younger than 8 months of age born during or entering into their first RSV season to prevent severe RSV disease.
- Available for infants if maternal RSV not given or if vaccine was given but delivery occurred prior to 34 weeks gestation.
- The RSV vaccine has shown an 80% reduction in RSV-related healthcare visits and hospitalizations.

1-866-769-3085 (NH Healthy Families)

1-844-265-1278 (Ambetter)

TDD/TTY: 1-855-742-0123

NHhealthyfamilies.com
ambetter.nhhealthyfamilies.com

Commitment to Communication

From your Provider Relations team.



2 Executive Park Drive • Bedford, NH 03110

Maternal RSV Vaccination (Abrysvo)

Pfizer's bivalent RSVpreF vaccine, Abrysvo is the only RSV vaccine approved for use during pregnancy.

- A single injection given to pregnant individuals at 32 weeks through 36 weeks gestational age have shown reduction in severe RSV infection in infants by 81% within 90 days of life, and 69% within 180 days of life.
- Should be given seasonally, September through January.
- May administer with other vaccines recommended during pregnancy, such as flu, COVID-19, and Tdap.
- Provides protection for infant if maternal vaccination occurred at least 14 days prior to birth.

Wellcare RSV Vaccinations Part D Advantage covers, allowing members to receive them at their local pharmacy.

Thank you for being a trusted partner in the healthcare decisions of those you care for.

Sincerely,

NH Healthy Families
Ambetter from NH Healthy Families

1-866-769-3085 (NH Healthy Families)
1-844-265-1278 (Ambetter)
TDD/TTY: 1-855-742-0123

NHhealthyfamilies.com
ambetter.nhhealthyfamilies.com